Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results , but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the ...

On March 31, 2026, William Blair upgraded 10x Genomics from “Market Perform” to “Outperform,” highlighting its best-in-class genomics platforms and exposure to growing demand for large-scale ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results , with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was less ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

View 10x Genomics Inc Class A TXG stock quote prices, financial information, real-time forecasts, and company news from CNN.

Genomics (TXG) has drawn investor attention after recent share price gains over the past week, month, and past 3 months, prompting closer scrutiny of its current valuation and business fundamentals.

Investors usually find it discouraging when an analyst cuts the price target on one of their stocks. In this instance, the cut to this company's shares was rather deep. It wasn't immediately apparent ...

Genomics (NasdaqGS:TXG) is collaborating with PerturbAI, NVIDIA, and the Allen Institute on what is described as the largest in vivo CRISPR brain atlas. The partnership combines 10x Genomics' single ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...

Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader ...

Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to ...